News & Media:Insights & News
- Open letter to the Duchenne Community, December 5, 2022
- Letter to the Duchenne Community: Strategic Update, September 30, 2022
- Letter to the Duchenne Community: Organizational Update to Advance Development of Duchenne Gene Therapy Pipeline Programs, April 27, 2022
- Letter to the Duchenne Community: Data and IGNITE DMD Phase I/II Clinical Trial Update, March 14, 2022
- Biotech 2050 Podcast: Episode 87 - Dr. Joel Schneider on Solid’s Patient-Centric Approach to Gene Therapy in Duchenne, February 1, 2022
- Letter to the Duchenne Community: IGNITE DMD Phase I/II Clinical Trial and 2022 Priorities, January 13, 2022
- Letter to the Duchenne Community: IGNITE DMD Phase I/II Clinical Trial and Pipeline Update, November 3, 2021
- Letter to the Duchenne Community: IGNITE DMD Phase I/II Clinical Trial and R&D Pipeline Development Update, August 16, 2021
- Letter to the Duchenne Community: IGNITE DMD Phase I/II Clinical Trial and Pipeline Update, May 14, 2021
- Letter to the Duchenne Community: Data and IGNITE DMD Clinical Trial Update, March 15, 2021
- Letter to the Duchenne Community: FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial, October 1, 2020
- Letter to the Duchenne Community: Update on SGT-001 Phase I/II Clinical Hold for IGNITE DMD Program, May 7, 2020
- Letter to the Duchenne Community: COVID-19 Update, March 27, 2020
- Letter to the Duchenne Community: Data and IGNITE DMD Clinical Trial Update, March 12, 2020
- Letter to the Duchenne Community: Organizational Changes, January 9, 2020
- Letter to the Duchenne Community: Data and IGNITE DMD Clinical Trial Update, December 18, 2019
- Letter to the Duchenne Community: Update on IGNITE DMD, November 12, 2019
- Letter to the Duchenne Community: Update on IGNITE DMD Clinical Trial, August 14, 2019
- Letter to the Duchenne Community: IGNITE DMD Status and New Clinical Sites, May 13, 2019
- Solid Partnered with New England Disabled Sports and JB’s Keys for the Adaptive Ski Program, April 16, 2019
- Solid Honors Rare Disease Day 2019, February 28, 2019
- Forbes: Sharing The Adaptive Ski Experience With The Biotech Community, February 25, 2019
- Letter to the Duchenne Community: Preliminary Data and Intention to Dose Escalate in IGNITE DMD, February 7, 2019
- Clear To Resume IGNITE DMD, June 18, 2018
- Letter to the Duchenne Community: Update on IGNITE DMD Clinical Trial, April 18, 2018
- Letter to the Duchenne Community About the Status of the IGNITE DMD Clinical Trial, March 14, 2018
- Solid Honors Rare Disease Day 2018, February 28, 2018
- Solid Biosciences Initiates Clinical Trial for Gene Transfer Candidate SGT-001 in Patients with Duchenne Muscular Dystrophy, November 30, 2017
- Letter To Duchenne Community About Solid’s First Clinical Trial, November 30, 2017
- Synpromics Announces Gene Therapy Research Partnership with Solid Biosciences, September 20, 2017
- Publication: Gene Transfer Corrects Severe Muscle Defects in Mice with Duchenne Muscular Dystrophy, July 27, 2017
- New Grant Funding from Save Our Sons and Join Our Boys, June 8, 2017
- Advancing Toward the Clinic, June 8, 2017
- Solid Biosciences Strengthens Leadership Team to Advance Programs For Duchenne Muscular Dystrophy, June 7, 2017
- New Preclinical Data Support SGT-001 As A Novel Treatment Approach For Duchenne Muscular Dystrophy, May 11, 2017
- Solid Biosciences Raises Up To $50 Million In Series C Financing, March 30, 2017
- Solid Honors Rare Disease Day 2017, March 14, 2017
- Duchenne Research Fund Provides Grant To Solid For Novel DMD Work, January 30, 2017
- Steps Forward For Duchenne Muscular Dystrophy, January 30, 2017
- Solid Adds Simvastatin Research Program To Therapeutic Pipeline, November 10, 2016
- Solid Biosciences Granted U.S. and E.U. Orphan Drug Designations for Lead Gene Therapy Candidate for Duchenne Muscular Dystrophy, October 24, 2016